摘要
在中国,丙型肝炎(简称丙肝)是一个严重的公共卫生问题。目前,在中国治疗丙肝的标准方法为干扰素联合利巴韦林。2017年4月中国批准了第一个用于丙肝治疗的直接抗病毒(direct-acting antivirals,DAA)药物。基于广泛的医疗需求,已有更多的DAA在近日被中国食品药品管理总局批准上市。一批DAA进入中国丙肝市场会带来丙肝治疗的临床效益。同时,也将带来相应的挑战。本文就这些挑战提出思考。中国丙肝人口众多。如果中国丙肝的问题得到很好的解决,这将有利于达到世界卫生组织提出的在2030年有效控制肝炎的总体目标。
Hepatitis C viral （HCV） infection is a significant public health concern to China. The current stand- ard of treatment is interferon based therapy. The first direct-acting antiviral （DAA） was approved late April 2017 in China. Given the unmet medical needs of HCV patients, a few more DAAs have been approved re cently by China Food and Drug Administration. These DAAs as a cluster, entering China in a relatively short time, would bring both clinical benefits and several challenges in the same time. This paper is created to ~d- dress these challenges. Given the size of HCV patients in China, the goal of eliminating viral hepatitis as a public health threat, including hepatitis C, by 2030 could not be achieved successfully if hepatitis C elimination program in China failed.
作者
魏来
李洪
贾继东
段钟平
谢青
庄辉
WEI Lai;LI Hong;JIA Ji-dong;DUAN Zhong-ping;XIE Qing;ZHUANG Hui(Peking University People＇s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy, Beijing, Chin)
出处
《中国病毒病杂志》
CAS
2017年第6期405-407,共3页
Chinese Journal of Viral Diseases
关键词
中国
丙型肝炎
丙型肝炎病毒
直接抗病毒药
可及性
安全性
China
Hepatitis, type C
Hepatitis C virus
Direct acting anti virals
Affordability
Safety
